Ferretti Francesca, Cannatelli Rosanna, Benucci Maurizio, Carmagnola Stefania, Clementi Emilio, Danelli Piergiorgio, Dilillo Dario, Fiorina Paolo, Galli Massimo, Gallieni Maurizio, Genovese Giovanni, Giorgi Valeria, Invernizzi Alessandro, Maconi Giovanni, Maier Jeanette A, Marzano Angelo V, Morpurgo Paola S, Nebuloni Manuela, Radovanovic Dejan, Riva Agostino, Rizzardini Giuliano, Sabiu Gianmarco, Santus Pierachille, Staurenghi Giovanni, Zuccotti Gianvincenzo, Sarzi-Puttini Pier Carlo, Ardizzone Sandro
Gastroenterology Unit, ASST Fatebenefratelli-Sacco, Department of Biomedical and Clinical Sciences (DIBIC) L. Sacco, Università degli Studi di Milano, Milan, Italy.
Rheumatology Unit, S. Giovanni di Dio Hospital, Azienda USL-Toscana Centro, Florence, Italy.
Front Immunol. 2021 Apr 15;12:656362. doi: 10.3389/fimmu.2021.656362. eCollection 2021.
Since March 2020, the outbreak of Sars-CoV-2 pandemic has changed medical practice and daily routine around the world. Huge efforts from pharmacological industries have led to the development of COVID-19 vaccines. In particular two mRNA vaccines, namely the BNT162b2 (Pfizer-BioNTech) and the mRNA-1273 (Moderna), and a viral-vectored vaccine, i.e. ChAdOx1 nCoV-19 (AstraZeneca), have recently been approved in Europe. Clinical trials on these vaccines have been published on the general population showing a high efficacy with minor adverse events. However, specific data about the efficacy and safety of these vaccines in patients with immune-mediated inflammatory diseases (IMIDs) are still lacking. Moreover, the limited availability of these vaccines requires prioritizing some vulnerable categories of patients compared to others. In this position paper, we propose the point of view about the management of COVID-19 vaccination from Italian experts on IMIDs and the identification of high-risk groups according to the different diseases and their chronic therapy.
自2020年3月以来，新型冠状病毒肺炎大流行的爆发改变了世界各地的医疗实践和日常生活。制药行业付出了巨大努力，促成了新冠疫苗的研发。特别是两种信使核糖核酸（mRNA）疫苗，即BNT162b2（辉瑞-生物科技公司）和mRNA-1273（莫德纳公司），以及一种病毒载体疫苗，即ChAdOx1 nCoV-19（阿斯利康公司），最近在欧洲获得批准。针对这些疫苗的临床试验已在普通人群中公布，显示出高疗效且不良事件较少。然而，关于这些疫苗在免疫介导的炎症性疾病（IMID）患者中的疗效和安全性的具体数据仍然缺乏。此外，这些疫苗供应有限，需要对某些弱势群体患者与其他患者进行优先排序。在本立场文件中，我们提出了意大利IMID专家关于新冠疫苗接种管理的观点，并根据不同疾病及其长期治疗方法确定了高危人群。
